Molecular Hydrogen for Outpatients with COVID-19 (Hydro-COVID): A Phase 3 Randomised, Triple-Blinded, Pragmatic, Placebo-Controlled, Multicentre Trial.
Yoann Gaboreau, Aleksandra Milovančev, Carole Rolland, Claire Eychenne, Jean-Pierre Alcaraz, Cordelia Ihl, Roseline Mazet, François Boucher, Celine Vermorel, Sergej M Ostojic, Jean-Christian Borel, Philippe Cinquin, Jean-Luc Bosson · Journal of clinical medicine · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 5 patients, HRW was not superior to placebo in preventing clinical worsening at day 14: in the H₂ group, 46.1% in the H₂ group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90-1.31]. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 5 patients. HRW was not superior to placebo in preventing clinical worsening at day 14: in the H₂ group, 46.1% in the H₂ group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90-1.31].
What the Researchers Studied
The researchers studied 5 patients. The study used a randomized, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
HRW was not superior to placebo in preventing clinical worsening at day 14: in the H₂ group, 46.1% in the H₂ group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90-1.31]. Due to its antioxidant, anti-inflammatory, anti-apoptosis, and anti-fatigue properties, molecular hydrogen (H₂) is potentially a novel therapeutic nutrient for patients with coronavirus acute disease 2019 (COVID-19).
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 5 patients. The reported sample size was 675. The study used a randomized, placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.